Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337571 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT00337571 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 218 participants.
The verdict
NCT00337571, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
Interventions
- DRUG Placebo
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2006-06-01 |
| Est. Completion | 2008-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00337571
The ClinicalTrials.gov registry entry for NCT00337571 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00337571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00337571 about?
NCT00337571 is a clinical study titled "Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)". This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
What is the current status of trial NCT00337571?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2006-06-01. Estimated completion is 2008-06-01.
What interventions are being tested in trial NCT00337571?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00337571?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.